TBPH

NEUTRAL

$16.72 Live

Theravance Biopharma, Inc. · NASDAQ

Target $17.2 (+2.9%)

$8.33 52W Range $21.03

TBPH Theravance Biopharma, Inc. - Fundamental Analysis

NEUTRAL

Console Chart News

TBPH Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$16.72

Analyst Target

$17.2

+2.9% Upside

52W High

$21.03

52W Low

$8.33

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026

Market cap

$860.96M

P/E

8.12

ROE

44.8%

Profit margin

98.5%

Debt/Equity

0.14

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

TBPH presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation trading very close to its Graham Number ($16.41) and Intrinsic Value ($14.42). While the company exhibits explosive revenue growth (144.7% YoY) and an exceptionally strong liquidity position (Current Ratio 10.93), these fundamentals are countered by bearish insider sentiment and a negative technical trend. The current price of $16.72 suggests the stock is fully valued based on deterministic models, leaving little margin of safety despite the low P/E ratio.

Key Strengths

Explosive YoY revenue growth of 144.70%

Exceptional liquidity with a Current Ratio of 10.93

Very low leverage with a Debt/Equity ratio of 0.14

Attractive P/E ratio (8.12) compared to the healthcare sector average

Recent positive shift in EPS growth (+220% YoY)

Key Risks

Strongly bearish insider activity with 5 sell transactions and 0 buys

Bearish technical trend (0/100 score)

Highly volatile quarterly earnings track record with frequent misses

Anomalous profit margin (98.54%) likely driven by non-recurring items

Current price is trading at a premium to the growth-based intrinsic value ($14.42)

AI Fair Value Estimate

Based on comprehensive analysis

$15.42

-7.8% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Fairly Valued Growth Play

Key drivers: Revenue acceleration, Balance sheet strength, Insider selling, Technical weakness

Confidence

80%

Value

70/100

Ref P/E, PEG, Graham Number

Positives

Low P/E of 8.12
Price is near Graham Number ($16.41)

Watchpoints

Trading slightly above intrinsic value

Future

85/100

Ref Growth rates

Positives

Triple-digit revenue growth
Positive EPS trajectory

Watchpoints

Earnings volatility

Past

45/100

Ref Historical trends

Positives

Recent 1Y price return of +83.1%

Watchpoints

Long history of negative EPS
5Y change is negative (-25.6%)

Health

65/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Extremely low debt
Massive current ratio

Watchpoints

Piotroski F-Score of 4/9 is only 'Stable'

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend payout

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$16.72

Analyst Target

$17.2

Upside/Downside

+2.9%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TBPH and closest competitors.

Updated 2026-04-20

Company	5Y	3Y	1Y	6M	1M	1W
TBPH Theravance Biopharma, Inc. Primary	-25.6%	+44.6%	+83.1%	+16.8%	+16.7%	+1.3%
INMD InMode Ltd. Peer	-67.3%	-61.5%	-4.0%	-11.4%	+3.0%	-1.9%
QDEL QuidelOrtho Corporation Peer	-89.6%	-86.0%	-49.5%	-54.8%	-25.4%	-8.2%
TALK Talkspace, Inc. Peer	-47.7%	+547.5%	+100.8%	+86.3%	+0.8%	0.0%
ABUS Arbutus Biopharma Corporation Peer	+34.8%	+48.0%	+34.4%	+0.9%	+3.2%	+6.6%

TBP

Theravance Biopharma, Inc.

Primary

-25.6%

+44.6%

+83.1%

+16.8%

+16.7%

+1.3%

INM

InMode Ltd.

Peer

-67.3%

-61.5%

-4.0%

-11.4%

+3.0%

-1.9%

QDE

QuidelOrtho Corporation

Peer

-89.6%

-86.0%

-49.5%

-54.8%

-25.4%

-8.2%

TAL

Talkspace, Inc.

Peer

-47.7%

+547.5%

+100.8%

+86.3%

+0.8%

0.0%

ABU

Arbutus Biopharma Corporation

Peer

+34.8%

+48.0%

+34.4%

+0.9%

+3.2%

+6.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

8.12

12.34

N/A

2.88

8.01

5.47

-297.73

$860.96M

Profitability

Profit margins and return metrics

Profit Margin 98.54%

Operating Margin 43.6%

Gross Margin 65.19%

ROE 44.84%

ROA -0.54%

Growth

Revenue and earnings growth rates

Revenue Growth +144.7%

Earnings Growth N/A

Q/Q Revenue Growth +144.7%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.14

Low debt

Current Ratio

10.93

Strong

Quick Ratio

10.73

Excellent

Cash/Share

$6.12

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Op. Margin

43.6%

Net Margin

133.0%

Total Assets

$0.5B

Liabilities

$0.2B

Equity

$0.3B

Debt/Equity

0.64x

Operating CF

$-0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07

$N/A

2026-03-19

$0.06

-81.9% surprise

2025-11-10

$0.04

+187.0% surprise

2025-08-12

$-0.08

+32.6% surprise

Healthcare Sector Comparison

Comparing TBPH against 497 companies in the Healthcare sector (27 bullish, 153 neutral, 317 bearish)

P/E Ratio

8.12

This Stock

84.2

Sector Avg

-90.4% (Discount)

Return on Equity (ROE)

44.84%

This Stock

-95.56%

Sector Avg

-146.9% (Below Avg)

Profit Margin

98.54%

This Stock

-15.89%

Sector Avg

-720.1% (Weaker)

Debt to Equity

0.14

This Stock

2.89

Sector Avg

-95.0% (Less Debt)

Revenue Growth

144.7%

This Stock

137.62%

Sector Avg

+5.1% (Growing)

Current Ratio

10.93

This Stock

4.67

Sector Avg

+134.2% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
TBPH Theravance Biopharma, Inc.	NEUTRAL	$860.96M	8.12	44.8%	98.5%	$16.72
INMD InMode Ltd.	NEUTRAL	$857.24M	9.46	13.5%	25.3%	$13.53	Compare
QDEL QuidelOrtho Corporation	BEARISH	$865.32M	-	-46.1%	-41.5%	$12.71	Compare
TALK Talkspace, Inc.	NEUTRAL	$865.45M	129.5	6.6%	3.4%	$5.18	Compare
ABUS Arbutus Biopharma Corporation	BEARISH	$872.03M	-	-38.5%	-237.9%	$4.53	Compare

TBPH Theravance...

NEUTRAL

Mkt Cap

$861M

P/E

8.1

ROE

44.8%

Price

$16.72

Compare with TBPH

QDEL QuidelOrtho Corporation

Compare with TBPH

Compare with TBPH

Compare with TBPH

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-04-01	FARNUM RHONDA	Officer	Stock Award	18,750	-
2026-04-01	SAWAF AZIZ	Chief Financial Officer	Stock Award	37,500	-
2026-04-01	GRIMAUD BRETT A	General Counsel	Stock Award	37,500	-
2026-04-01	WINNINGHAM RICK E	Chief Executive Officer	Stock Award	75,000	-
2026-03-16	FARNUM RHONDA	Officer	Sale	31,067	$433,637
2025-12-03	FARNUM RHONDA	Officer	Sale	31,067	$582,501
2025-11-26	BROSHY ERAN	Director	Sale	29,501	$590,020
2025-11-19	WINNINGHAM RICK E	Chief Executive Officer	Gift	9,900	-
2025-11-11	BROSHY ERAN	Director	Sale	59,000	$1,068,250
2025-11-11	BROSHY ERAN	Director	Sale	45,000	$809,250
2025-11-11	BROSHY ERAN	Director	Option Exercise	14,000	$142,100

FARNUM RHONDA

Officer

Stock Award

2026-04-01

18,750 shares

SAWAF AZIZ

Chief Financial Officer

Stock Award

2026-04-01

37,500 shares

GRIMAUD BRETT A

General Counsel

Stock Award

2026-04-01

37,500 shares

WINNINGHAM RICK E

Chief Executive Officer

Stock Award

2026-04-01

75,000 shares

FARNUM RHONDA

Officer

Sell

2026-03-16

31,067 shares · $433,637

FARNUM RHONDA

Officer

Sell

2025-12-03

31,067 shares · $582,501

BROSHY ERAN

Director

Sell

2025-11-26

29,501 shares · $590,020

WINNINGHAM RICK E

Chief Executive Officer

Gift

2025-11-19

9,900 shares

BROSHY ERAN

Director

Sell

2025-11-11

59,000 shares · $1,068,250

BROSHY ERAN

Director

Sell

2025-11-11

45,000 shares · $809,250

BROSHY ERAN

Director

Option Exercise

2025-11-11

14,000 shares · $142,100

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

FORM 8-K

2026-03-30

TBPH filed an 8-K on March 30, 2026, likely to announce its quarterly financial results.

10-K

2026-03-23

TBPH filed its annual 10-K report on March 23, 2026. The provided excerpts do not contain specific financial metrics or detailed risk disclosures.

8-K

FORM 8-K

2026-03-19

8-K

FORM 8-K

2026-03-03

TBPH filed an 8-K on March 3, 2026, likely to announce its annual financial results for the fiscal year ended December 31, 2025.

8-K

FORM 8-K

2026-01-12

8-K

FORM 8-K

2025-12-08

10-Q

2025-11-12

TBPH filed its quarterly 10-Q report on November 12, 2025. While specific financial highlights were not provided in the excerpt, the filing includes a dedicated section detailing the company's risk factors.

8-K

FORM 8-K

2025-11-10

8-K

FORM 8-K

2025-08-25

8-K

FORM 8-K

2025-08-20

TBPH filed a Form 8-K on August 20, 2025, likely to announce its second-quarter financial results.

10-Q

2025-08-13

8-K

FORM 8-K

2025-08-12

8-K

FORM 8-K

2025-06-26

8-K

FORM 8-K

2025-06-06

8-K

FORM 8-K

2025-06-02

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

5 analysts

B. Riley Securities

2026-04-07

Maintains

Neutral Neutral

TD Cowen

2026-03-23

Maintains

Hold Hold

BTIG

2026-03-20

reit

Buy Buy

Oppenheimer

2026-03-05

down

Outperform Perform

HC Wainwright & Co.

2026-03-04

Maintains

Buy Buy

B. Riley Securities

2026-03-04

down

Buy Neutral

BTIG

2026-03-03

Maintains

Buy Buy

HC Wainwright & Co.

2026-03-02

Maintains

Buy Buy

BTIG

2026-02-03

reit

Buy Buy

Oppenheimer

2025-12-03

init

Outperform

Past News Coverage

Recent headlines mentioning TBPH from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

TBPH

TBPH Theravance Biopharma, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!